Bioresorbable Vascular Scaffold Technology Benefits from Healthy Skepticism

Journal of the American College of Cardiology

Volumn 67, Issue 8, 2016, Pages 932-935

  Cassese, Salvatore ^a   Kastrati, Adnan ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

bioresorbable vascular scaffold; coronary artery disease; drug eluting stents; scaffold; stent; thrombosis

Indexed keywords

BIORESORBABLE SCAFFOLD; BIORESORBABLE VASCULAR SCAFFOLD; BLOOD VESSEL DIAMETER; CLINICAL PROTOCOL; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DRUG THERAPY; DUAL ANTIPLATELET THERAPY; EDITORIAL; EVEROLIMUS ELUTING CORONARY STENT; HUMAN; META ANALYSIS (TOPIC); PATIENT RISK; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STENT THROMBOSIS; ACUTE CORONARY SYNDROME; ADVERSE EFFECTS; BIODEGRADABLE IMPLANT; CORONARY RESTENOSIS; FEMALE; GRAFT OCCLUSION, VASCULAR; MALE; TISSUE SCAFFOLD;

ABSORBABLE IMPLANTS; ACUTE CORONARY SYNDROME; CORONARY RESTENOSIS; FEMALE; GRAFT OCCLUSION, VASCULAR; HUMANS; MALE; TISSUE SCAFFOLDS;

EID: 84958999550     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.12.020     Document Type: Editorial

References (19)

1. S. Windecker, P. Kolh, F. Alfonso, and et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Eur Heart J 35 2014 2541 2619
2. F. Otsuka, R.A. Byrne, K. Yahagi, and et al. Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment Eur Heart J 36 2015 2147 2159
3. J. Iqbal, Y. Onuma, J. Ormiston, A. Abizaid, R. Waksman, and P. Serruys Bioresorbable scaffolds: rationale, current status, challenges, and future Eur Heart J 35 2014 765 776
4. S. Cassese, R.A. Byrne, G. Ndrepepa, and et al. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials Lancet 2015 Nov 16 [E-pub ahead of print]
5. D. Capodanno, T. Gori, H. Nef, and et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry EuroIntervention 10 2015 1144 1153
6. R.P. Kraak, M.E. Hassell, M.J. Grundeken, and et al. Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold (BVS) in real-world practice: the AMC Single Centre Real World PCI Registry EuroIntervention 10 2015 1160 1168
7. S. Brugaletta, T. Gori, A.F. Low, and et al. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (Bioresorbable Vascular Scaffold-A Clinical Evaluation of Everolimus Eluting Coronary Stents in the Treatment of Patients With ST-Segment Elevation Myocardial Infarction) J Am Coll Cardiol Intv 8 2015 189 197
8. S. Puricel, F. Cuculi, M. Weissner, and et al. Bioresorbable coronary scaffold thrombosis: multicenter comprehensive analysis of clinical presentation, mechanisms, and predictors J Am Coll Cardiol 67 2016 921 931
9. T. Gori, J. Wiebe, D. Capodanno, and et al. Early and midterm outcomes of bioresorbable vascular scaffolds for ostial coronary lesions: insights from the GHOST-EU registry EuroIntervention 2015 Sep 8 [E-pub ahead of print]
10. M.K. Lam, H. Sen, K. Tandjung, and et al. Clinical outcome of patients with implantation of second-generation drug-eluting stents in the right coronary ostium: insights from 2-year follow-up of the TWENTE trial Catheter Cardiovasc Interv 85 2015 524 531
11. J. Ormiston, P. Motreff, O. Darremont, B. Webber, P. Guerin, and M. Webster Bioresorbable scaffolds on the bench EuroIntervention 11 Suppl V 2015 V166 V169
12. T. Kimura, K. Kozuma, K. Tanabe, and et al. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan Eur Heart J 36 2015 3332 3342
13. S. Ellis, D. Kereiakes, D. Metzger, and et al. Everolimus-eluting bioresorbable scaffolds for coronary artery disease N Engl J Med 373 2015 1905 1915
14. J.A. Ormiston, B. Webber, B. Ubod, O. Darremont, and M.W. Webster An independent bench comparison of two bioresorbable drug-eluting coronary scaffolds (Absorb and DESolve) with a durable metallic drug-eluting stent (ML8/Xpedition) EuroIntervention 11 2015 60 67
15. A. Mattesini, G.G. Secco, G. Dall'Ara, and et al. ABSORB biodegradable stents versus second-generation metal stents: a comparison study of 100 complex lesions treated under OCT guidance J Am Coll Cardiol Intv 7 2014 741 750
16. L. Räber, S. Brugaletta, K. Yamaji, and et al. Very late scaffold thrombosis: intracoronary imaging and histopathological and spectroscopic findings J Am Coll Cardiol 66 2015 1901 1914
17. P. Genereux, D.R. Rutledge, T. Palmerini, and et al. Stent thrombosis and dual antiplatelet therapy interruption with everolimus-eluting stents: insights from the Xience V coronary stent system trials Circ Cardiovasc Interv 8 2015 e001362
18. D. Capodanno, M. Joner, and M. Zimarino What about the risk of thrombosis with bioresorbable scaffolds? EuroIntervention 11 Suppl V 2015 V181 V184
19. R.A. Byrne, M. Joner, and A. Kastrati Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Gruntzig Lecture ESC 2014 Eur Heart J 36 2015 3320 3331